Home

MARKSMAN HEALTHCARE COMMUNICATIONS | A DATA SCIENCE COMPANY

In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever increasing costs and abating healthcare budgets, payers have a significant and growing influence on a product’s commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product’s success.

MarksMan Healthcare Communications is a Health Economic and Outcomes Research (HEOR), Medical Writing and Data Analytics consulting, committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories. We utilize the expertise of our trained professionals to provide accurate, consistent and concise product, disease and therapeutic area information.

Our experienced and trained analytics team provides HEOR, Real Wold Evidence (RWE) and market access support to large and small life science companies. We further provide services pertaining to “Medical Affairs, Data Curation, Patient Chart Abstraction, Data Analytics, Pharmacovigilance and Regulatory Writing”

OUR SERVICES

A scientific research consulting committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories.

HEOR

Medical Affairs

Data Curation

Patient Registry

Data Analytics

LATEST FROM BLOG

15Oct 2020

During the course of any research, most of the relevant literature pertaining to a research question is retrieved though searching of recognised databases. However, in addition to this, searching of grey literature can add value to the depth of the research by providing information from varied sources. Grey literature search is an important, but often […]

LATEST PRESENTATIONS

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Everolimus as a Combination Therapy in the Treatment of Metastatic Breast Cancer: A Systemic Review and Meta-analysis

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Vedolizumab in the Treatment of Ulcerative Colitis: A Systemic Review and Meta-analysis

  • DIA 2018 Global Annual Meeting 2018, June 24-28, 2018, Boston, USA

    Role of Social Media in Patient Reported Outcomes (PRO) Research

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Enzalutamide in Metastatic Prostate Cancer Patients: A Systematic Review and Meta-Analysis

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Adaptive Licensing and Real World Evidence (RWE)

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    A Comparison of AMSTAR and ROBIS tools for Methodological Quality Assessment of Systematic reviews of Alzheimer’s Disease

WHAT OUR CLIENT SAY

OUR COLLABORATIONS